You will find reconciliations of our historic non-GAAP measures in the appendix of the pages that accompany this presentation, which are available on Bausch Health Companies Inc.'s Investor Relations website. Finally, the financial guidance in this presentation is effective as of today only. We do not undertake any obligation to update guidance. Our discussion today, Wednesday, October 29, will focus on Bausch Health Companies Inc. excluding Bausch + Lomb. However, we will briefly comment on Bausch + Lomb's ...

Third Quarter Consolidated Revenues of $2.68 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $179 million and GAAP Net Income of $181 million Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $986 million, including an $81 million acquired In-Process Research & Development ("IPR&D") charge, up 8% on a Reported basis over the prior year period BAUSCH HEALTH EXCLUDING BAUSCH + LOMB THI ...